Systemic Lupus Erythematosus-related Lung Disease
Thieme. All rights reserved..
Systemic Lupus Erythematosus (SLE) is a multifaceted, multisystem autoimmune disorder with diverse clinical expressions. While prevalence reports vary widely, pulmonary involvement accounts for significant morbidity and mortality in SLE. This comprehensive review explores the spectrum of pulmonary disease in SLE, including upper airway manifestations (e.g., laryngeal affection), lower airway conditions (e.g., bronchitis, bronchiolitis, bronchiectasis), parenchymal diseases (e.g., interstitial lung disease, acute lupus pneumonitis, diffuse alveolar hemorrhage), pleural diseases (e.g., serositis, shrinking lung syndrome), and vascular diseases (e.g., pulmonary arterial hypertension, pulmonary embolism, acute reversible hypoxemia syndrome). We discuss diagnostic modalities, treatment strategies, and prognosis for each pulmonary manifestation. With diagnostics remaining a challenge and with the absence of standardized treatment guidelines, we emphasize the need for evidence-based guidelines to optimize patient care and improve outcomes in this complex disease.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Seminars in respiratory and critical care medicine - (2024) vom: 28. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Bendstrup, Elisabeth [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 28.03.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1055/s-0044-1782653 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370374436 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM370374436 | ||
003 | DE-627 | ||
005 | 20240330002736.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240330s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1055/s-0044-1782653 |2 doi | |
028 | 5 | 2 | |a pubmed24n1355.xml |
035 | |a (DE-627)NLM370374436 | ||
035 | |a (NLM)38547915 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Bendstrup, Elisabeth |e verfasserin |4 aut | |
245 | 1 | 0 | |a Systemic Lupus Erythematosus-related Lung Disease |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 28.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a Thieme. All rights reserved. | ||
520 | |a Systemic Lupus Erythematosus (SLE) is a multifaceted, multisystem autoimmune disorder with diverse clinical expressions. While prevalence reports vary widely, pulmonary involvement accounts for significant morbidity and mortality in SLE. This comprehensive review explores the spectrum of pulmonary disease in SLE, including upper airway manifestations (e.g., laryngeal affection), lower airway conditions (e.g., bronchitis, bronchiolitis, bronchiectasis), parenchymal diseases (e.g., interstitial lung disease, acute lupus pneumonitis, diffuse alveolar hemorrhage), pleural diseases (e.g., serositis, shrinking lung syndrome), and vascular diseases (e.g., pulmonary arterial hypertension, pulmonary embolism, acute reversible hypoxemia syndrome). We discuss diagnostic modalities, treatment strategies, and prognosis for each pulmonary manifestation. With diagnostics remaining a challenge and with the absence of standardized treatment guidelines, we emphasize the need for evidence-based guidelines to optimize patient care and improve outcomes in this complex disease | ||
650 | 4 | |a Journal Article | |
700 | 1 | |a Lynn, Evelyn |e verfasserin |4 aut | |
700 | 1 | |a Troldborg, Anne |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Seminars in respiratory and critical care medicine |d 1997 |g (2024) vom: 28. März |w (DE-627)NLM093752415 |x 1098-9048 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:28 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.1055/s-0044-1782653 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 28 |c 03 |